Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept TAE in Type 3 Neovascularization
NCT04655482Phase 4Unknown
- Sponsor
- Kim's Eye Hospital
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in age-related macular degeneration (AMD), sponsored by Kim's Eye Hospital. Primary endpoint: Change in best-corrected visual acuity at 76 weeks. Status: unknown.
02
Drugs
aflibercept
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04655482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655482.